In Treating Wet AMD, Cheaper Anti-cancer Drug Equally Effective as Expensive Drug

In treating the most common cause of blindness in older adults, an anti-cancer drug has been proven to be equally as effective and as a more expensive drug specifically formulated for this purpose.

The results of a two-year trial, led by Queen's scientist Professor Usha Chakravarthy, and published in The Lancet today (Friday 19 July), show that two drug treatments Lucentis and Avastin are equally effective in treating neovascular or wet age-related macular degeneration (wet AMD). Wet AMD is a common cause of sight loss in older people with at least 23,000 older people diagnosed with the condition in the UK each year.

New Anti-cancer Drug Unveiled
Cuba's Labiofam Entrepreneurial Group has unveiled a new anti-cancer drug that is more effective than its predecessor.

Without treatment two thirds of people with this condition will experience severe loss of sight within two years of being diagnosed. Lucentis, the drug most commonly used in the UK at present to treat wet AMD, costs about £700 per injection and Avastin costs about £60 per injection.

The NHS could save £84.5 million annually based on injecting 17,295 eyes each year by switching from Lucentis to Avastin. Avastin is already used to treat wet AMD in some parts of the UK and extensively elsewhere in the world and also for other eye conditions.

Over the past five years, a team of scientists and eye specialists from 23 hospitals and UK universities, including Queen's University Belfast, University of Bristol, University of Liverpool, University of Southampton and University of Oxford, have investigated whether Lucentis and Avastin and the way they are given are equally effective and safe.

Study Says Grapefruit Nanoparticles can Deliver Anti-cancer Drugs
Engineered nanoparticles derived from grapefruit can be used to deliver anti-cancer and other drugs to tumor cells, say researchers.

610 people with wet AMD entered a two-year trial known as IVAN which is one of the largest ever carried out in the field of eye disease in the UK. Patients received injections of the drug into the affected eye every month for the first three months. Patients were then subdivided to receive the injections at every visit (monthly group) or only if the specialist decided there was persistent disease activity (as needed group).

The IVAN study's two year results show that sight was equally well preserved with either of the two drugs. Giving the treatment regularly every month, resulted in slightly better levels of sight which was detected through testing of near visual acuity and contrast sensitivity.

Neuroblastomas Vulnerable to a New Class of Anti-Cancer Drugs
The efficacy of new anti-cancer drugs known as BET bromodomain inhibitors may be undertood by an irregularity within neuroblastoma cells in the neuroblastoma tumor, a childhood cancer.

The 'as needed' group received on average 13 injections over the two year period compared to 23 for the monthly treatment group. However, continuous treatment caused a higher proportion of eyes to develop a condition known as geographic atrophy which is a thinning of the retina and its blood supply.

Source-Eurekalert

Genetically Engineered Algae Used to Make Complex Anti-cancer Drug
To treat cancer, biologists at UC San Diego have succeeded in genetically engineering algae to produce a complex and expensive human therapeutic drug.